Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Pre-Tax Margin

Income before tax as a percentage of revenue.

Biogen Inc.NASDAQ: BIIB

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to 4.8%

Pre-tax margin was 4.8% in Q2 FY2026, down 23.3 pp from a year earlier. On a trailing-twelve-month basis it was 8.6%, down 9.4 pp year over year. Over 3 fiscal years it narrowed by 21.0 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
4.8%-10.4 pp QoQ
Last fiscal yearDec 2025
14.3%-5.4 pp YoY
LTMJun 2026
8.6%-9.4 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-23.3 pp——
1 year-5.4 pp——
3 years-21.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
14.3%
Year-over-year change
-5.4pp

Pre-Tax Margin vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's LTM Jun 2026 pre-tax margin of 8.6% is the 8th highest of the 11 companies compared; the peer median is 24.1%.
  • Its year-over-year change of -9.4 pp is the 8th highest of 11, against a peer median of -1.2 pp.
  • Over three fiscal years its change of -21.0 pp compares with a peer median of +4.2 pp.
BIIB Competitors Peer median
Pre-Tax Margin for BIIB and competitors
Company Period LTM level YoY 3-year change
UTHRUnited Therapeutics CorporationLTM Jun 202649.9% -2.7 pp+4.8 pp
LLYEli Lilly and CompanyLTM Jun 202642.2% +10.5 pp+15.6 pp
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 202636.6% -1.3 pp-8.9 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202633.3% -1.0 pp-3.4 pp
AMGNAmgen Inc.LTM Jun 202627.0% +5.7 pp-3.5 pp
AZNAstraZeneca PLCLTM Sep 202621.3% +1.6 pp+15.5 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202616.6% +32.1 pp+117.3 pp
BIIBBiogen Inc.LTM Jun 20268.6% -9.4 pp-21.0 pp
PFEPfizer Inc.LTM Jun 20266.6% -9.9 pp-22.3 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-6.6% -44.4 pp+124.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.7% -29.9 pp+3.7 pp
Peer median (excluding BIIB) 24.1%-1.2 pp+4.2 pp

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.98B10.17B9.84B9.68B9.81B
Cost of Revenue2.11B2.28B2.53B2.31B2.9B
Gross Profit8.87B7.9B7.3B7.37B6.91B
Gross Margin80.8%77.6%74.2%76.1%70.5%
Research & Development3.4B2.6B2.7B2.49B1.95B
Selling, General & Admin2.68B2.41B2.5B2.39B2.43B
Operating Expenses6.08B5.01B5.2B4.88B5.04B
Depreciation & Amortization487.7M518.4M494.8M673.2M779.9M
EBITDA3.92B3.54B2.38B3B2.95B
EBITDA Margin35.7%34.8%24.2%31.0%30.0%
Operating Income2.79B2.89B2.1B2.49B1.88B
Operating Margin25.4%28.4%21.3%25.7%19.1%
Interest Income11M89.3M276.5M67.6M87.8M
Interest Expense253.6M246.6M246.9M250.3M246M
Other Income / Expenses(1.01B)705.3M(800.5M)(584.3M)(476M)
Income Before Tax1.78B3.59B1.3B1.91B1.4B
Pre-Tax Margin16.2%35.3%13.2%19.7%14.3%
Income Tax Expense52.5M632.8M135.3M273.8M108.11M
Net Income1.56B3.05B1.16B1.63B1.29B
Net Margin14.2%29.9%11.8%16.9%13.2%
EPS (Basic)10.4420.978.0211.208.85
EPS (Diluted)10.4020.877.9711.198.83
Weighted Avg Shares149.1M145.3M144.7M145.7M146.7M
Weighted Avg Shares (Diluted)149.6M146M145.6M145.9M146.7M

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.